Table 1 Demographic and clinical characteristics of FTD patients according to serum anti-GluA3 antibody dosage.
From: Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target
Variable | FTD (all) | FTD-GluA3+ | FTD-GluA3− | P* |
|---|---|---|---|---|
Number | 175 | 41 | 134 | Â |
Age onset, y | 62.9 ± 7.0 | 62.1 ± 7.5 | 63.2 ± 6.8 | n.s. |
Age at diagnosis, y | 65.7 ± 7.2 | 64.8 ± 7.7 | 65.9 ± 7.1 | n.s. |
Sex, F% | 40.6 (71) | 34.1 (14) | 42.5 (57) | n.s. |
FH (AD), % | 7.4 (13) | 4.8 (2) | 8.2 (11) | n.s. |
Education, y | 8.9 ± 4.3 | 9.1 ± 4.0 | 8.8 ± 4.3 | n.s. |
bvFTD, % | 70.9 (124) | 63.4 (26) | 73.1 (98) | n.s. |
CSF Abeta (pg/ml) | 839.3 ± 404.5 | 779.2 ± 339.3 | 859.9 ± 425.0 | n.s. |
CSF Tau (pg/ml) | 403.4 ± 278.5 | 332.4 ± 241.5 | 426.3 ± 287.3 | n.s. |
CSF pTau (pg/ml) | 61.2 ± 59.4 | 48.9 ± 31.4 | 65.1 ± 65.5 | n.s. |
